Bile acid scaffold engineering reveals an androstane-triol derivative as a potent immunomodulator with therapeutic efficacy in EAE.

Consistent with our initial findings, BA59 again significantly ameliorated experimental disease and showed a clear trend toward overall clinical improvement (AUC = 30.73 ± 15.27, n = 22 vs. 38.95 ± 14.21, n = 22, p = 0.0713) (Fig. 3 B), whereas BA26 remained ineffective even at the higher dose (Figure S12).

also in 19,460 other papers

Under these conditions, BA59 produced a measurable reduction in clinical severity after 10 days of treatment, leading to an overall trend toward clinical improvement (AUC = 24.29 ± 10.20, n = 12, p = 0.093) compared with vehicle-treated controls (33.08 ± 10.58, n = 12) (Figure S11).

also in 4,871 other papers

Although BA26 produced modest improvements over the positive control (20.62 ± 41.22%), that difference did not reach statistical significance.

also in 111,027 other papers